Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | Update on IMGN632: CD123 antibody-drug conjugate for R/R AML and BPDCN

Naval Daver • 29 May 2020
ASCO 2020
Acute Myeloid Leukemia Leukemia Antibodies Azacitidine IMGN632 Venetoclax

Naval Daver, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the Phase I/II study (NCT03386513) of IMGN632, a novel CD123-targeting antibody-drug conjugate, in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML), blastic plasmacytoid dendritic cell neoplasm (BPDCN), and other CD123-positive malignancies. Additionally, Dr Daver outlines the Phase Ib/II study of IMGN632 study (NCT04086264) as monotherapy or in combination with venetoclax and/or azacitidine for patients with CD123-positive AML. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Naval Daver

Targeting FLT3-mutant AML: frontline strategy, MRD-guided transplant, and RAS-targeted approaches
12:28
Targeting FLT3-mutant AML: frontline strategy, MRD-guided transplant, and RAS-targeted approaches
Alexander Perl et al. • 20 Sep 2026
VICEROY study: azacitidine, venetoclax, and gilteritinib in FLT3-mutated AML
3:31
VICEROY study: azacitidine, venetoclax, and gilteritinib in FLT3-mutated AML
Naval Daver • 8 Dec 2025
Pivekimab sunirine w/ venetoclax + azacitidine in unfit patients with newly diagnosed AML
2:25
Pivekimab sunirine w/ venetoclax + azacitidine in unfit patients with newly diagnosed AML
Naval Daver • 8 Dec 2025
Enzomenib monotherapy in R/R AML: updated results from a Phase I/II study
2:30
Enzomenib monotherapy in R/R AML: updated results from a Phase I/II study
Naval Daver • 8 Dec 2025

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals